Blair William & Co. IL Acquires 4,042 Shares of Penumbra, Inc. $PEN

Blair William & Co. IL lifted its holdings in shares of Penumbra, Inc. (NYSE:PEN) by 62.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 10,564 shares of the company’s stock after acquiring an additional 4,042 shares during the period. Blair William & Co. IL’s holdings in Penumbra were worth $2,711,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PEN. Synergy Investment Management LLC bought a new position in shares of Penumbra during the 1st quarter worth about $27,000. First Horizon Advisors Inc. lifted its holdings in shares of Penumbra by 404.8% during the 1st quarter. First Horizon Advisors Inc. now owns 106 shares of the company’s stock worth $28,000 after acquiring an additional 85 shares during the period. AlphaQuest LLC bought a new position in shares of Penumbra during the 1st quarter worth about $66,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Penumbra during the 1st quarter worth about $76,000. Finally, Meeder Asset Management Inc. lifted its holdings in shares of Penumbra by 1,966.7% during the 1st quarter. Meeder Asset Management Inc. now owns 372 shares of the company’s stock worth $99,000 after acquiring an additional 354 shares during the period. 88.88% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PEN. William Blair raised shares of Penumbra to a “strong-buy” rating in a report on Friday, July 18th. Royal Bank Of Canada dropped their target price on shares of Penumbra from $330.00 to $325.00 and set an “outperform” rating for the company in a research note on Wednesday, July 30th. Robert W. Baird boosted their target price on shares of Penumbra from $283.00 to $285.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 30th. Truist Financial set a $310.00 price target on shares of Penumbra and gave the stock a “buy” rating in a research report on Wednesday, July 30th. Finally, Wall Street Zen upgraded shares of Penumbra from a “hold” rating to a “buy” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $303.44.

Penumbra Stock Down 2.9%

Shares of NYSE PEN opened at $253.02 on Tuesday. The stock has a market cap of $9.87 billion, a P/E ratio of 67.29, a P/E/G ratio of 2.35 and a beta of 0.41. The firm has a 50 day moving average price of $259.47 and a 200 day moving average price of $261.86. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.04 and a current ratio of 6.75. Penumbra, Inc. has a 52-week low of $198.68 and a 52-week high of $310.00.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.05. The firm had revenue of $339.46 million during the quarter, compared to analysts’ expectations of $327.37 million. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The business’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.64 earnings per share. Penumbra has set its FY 2025 guidance at EPS. Analysts expect that Penumbra, Inc. will post 3.67 EPS for the current year.

Insider Activity

In related news, Director Arani Bose sold 12,000 shares of the business’s stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $250.65, for a total value of $3,007,800.00. Following the sale, the director directly owned 558 shares of the company’s stock, valued at approximately $139,862.70. The trade was a 95.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Maggie Yuen sold 2,000 shares of the company’s stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $250.00, for a total transaction of $500,000.00. Following the completion of the transaction, the chief financial officer directly owned 12,943 shares of the company’s stock, valued at approximately $3,235,750. The trade was a 13.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 80,610 shares of company stock valued at $20,088,148. 5.00% of the stock is currently owned by company insiders.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.